Can I legally buy cosyntropin online and import it to the EU?

No. Importing cosyntropin from overseas for personal use violates EU pharmaceutical law. Even if purchased legally in the US, it cannot legally enter the EU market or be dispensed. Customs may seize it. Always consult your national medicines regulator before attempting to import unapproved compounds.

Why is cosyntropin approved in the US but not the EU?

The FDA and EMA follow different approval timelines and evidentiary standards. Cosyntropin was approved by the FDA decades ago for diagnostic ACTH testing. The EMA has never received a manufacturer application for it, likely because the EU market is smaller and the diagnostic use case is narrow, making it economically unviable to pursue EU approval.

Are there legal EU alternatives to cosyntropin for adrenal testing?

Yes. EU clinicians use alternative diagnostic approaches to assess adrenal function, including other ACTH stimulation methods, biochemical markers, and imaging. These remain within approved regulatory frameworks. Consult an endocrinologist to explore options appropriate for your clinical situation.

Could cosyntropin become legal in the EU in the future?

Theoretically, yes—if a pharmaceutical manufacturer pursued and obtained EMA marketing authorisation. However, this is unlikely without significant commercial interest. The narrow diagnostic use case and availability of alternatives make investment in EMA approval economically unattractive for manufacturers.

What's the difference between 'illegal' and 'not authorised'?

"Not authorised" means it lacks regulatory approval—it's not a licensed product in the EU. "Illegal" means it violates law. Cosyntropin is both: it has no approval status and selling/dispensing it violates pharmaceutical regulations in EU member states.

Is Cosyntropin Legal in the EU? Status & Regulations

Cosyntropin is not authorised for use in the European Union. While the compound is FDA-approved in the United States and used clinically there, the European Medicines Agency (EMA) has not granted marketing authorisation for cosyntropin in EU member states. This means it cannot be legally prescribed or dispensed through standard pharmacy channels in most of Europe. However, understanding its regulatory status—and why it differs across jurisdictions—helps clarify what legal options exist for patients and practitioners in the EU who may be interested in this ACTH analog.

Cosyntropin's Regulatory Status in Europe

Cosyntropin, a synthetic analog of adrenocorticotropic hormone (ACTH), holds a unique position in global pharmaceuticals: it is approved in some jurisdictions but notably absent from the EU's regulatory framework. The EMA has not issued a marketing authorisation for cosyntropin, meaning it does not appear on the list of approved medicinal products in any EU member state.

This absence doesn't mean the compound is illegal to possess in all contexts—it means it cannot be manufactured, marketed, or dispensed as a licensed pharmaceutical product within the EU. The distinction matters for patients, clinicians, and researchers.

Why Isn't Cosyntropin Authorised in the EU?

The EMA's lack of authorisation for cosyntropin reflects a combination of factors:

Limited Commercial Interest: Unlike the United States, where cosyntropin is FDA-approved and used primarily in diagnostic testing, the European pharmaceutical market has fewer incentives for manufacturers to pursue EMA approval. The compound's primary use case—ACTH stimulation testing in endocrinology—is relatively narrow.

Regulatory Pathway Differences: The EMA's approval process differs significantly from the FDA's. Companies seeking EU authorisation must navigate more stringent comparative efficacy data requirements and post-authorisation surveillance expectations. For a diagnostic agent with limited market size, the cost-benefit analysis often doesn't favour pursuing EMA approval.

Availability of Alternatives: In many EU countries, clinicians can access alternative diagnostic agents or use other peptide-based therapeutics within the approved framework, reducing the urgency for cosyntropin specifically.

Global Approval Context

To understand cosyntropin's EU status, it helps to see where it is approved:

United States: Cosyntropin is FDA-approved and available as a branded pharmaceutical. It's used in the cosyntropin stimulation test (CST), a diagnostic procedure to assess adrenal function and screen for adrenal insufficiency.

Canada: Health Canada has not approved cosyntropin for therapeutic use.

EU Member States: No EMA marketing authorisation exists.

Despite these regulatory gaps, clinical trials have demonstrated cosyntropin's utility in diagnostic endocrinology. The compound has been studied in at least 38 clinical trials globally, many of which established its role in assessing pituitary and adrenal function.

What Does "Not Authorised" Mean for EU Patients?

The absence of EMA authorisation carries specific implications:

No Standard Prescription Access: Patients in the EU cannot obtain cosyntropin through regular pharmacy channels with a standard prescription. It is not listed in national formularies or reimbursement systems.

Potential Research or Compassionate Use Pathways: Some EU countries may permit access to unapproved compounds through:

Named patient programmes (where a manufacturer makes exceptions for individuals)
Compassionate use regulations (varies by member state)
Clinical trial enrolment (if an active trial exists)

These routes are case-by-case and require specific regulatory justification.

Import and Possession Ambiguity: Importing cosyntropin from the US for personal use falls into a legal grey area in most EU jurisdictions. While not explicitly illegal to possess in many cases, selling, dispensing, or marketing it would violate pharmaceutical regulations. The legal status depends on member state law and intended use.

Regulatory Pathways in the EU

If a manufacturer or research organisation wanted to pursue EMA authorisation for cosyntropin, the pathway would involve:

Centralised Procedure: Submitting a Marketing Authorisation Application (MAA) to the EMA, which reviews data on quality, safety, and efficacy. This is the standard route for new compounds.

Demonstration of Need: Providing evidence that cosyntropin offers clinical or diagnostic advantages over existing alternatives in the EU market.

Comparative Efficacy Data: The EMA typically requires head-to-head comparisons with existing diagnostic agents to justify approval.

Given the narrow diagnostic use case and limited commercial interest, no manufacturer has pursued this pathway in recent decades.

Approved Peptides and Alternatives in the EU

While cosyntropin is not available, the EU regulatory framework has approved numerous peptide-based therapeutics for other indications. For example, abaloparatide is authorised for osteoporosis treatment, and therapeutic peptides like bacitracin are available through specific regulated pathways.

For diagnostic endocrinology, EU clinicians may use alternative approaches to assess adrenal and pituitary function, such as:

Other ACTH analogs (if available)
Alternative stimulation tests
Imaging and biochemical markers

These alternatives maintain clinical utility while remaining within the approved regulatory framework.

Summary: Legal Status

Cosyntropin is not legal to prescribe, dispense, or market in the EU. It has no EMA marketing authorisation and is not registered in any EU member state's national medicines register. This makes it unavailable through standard legal pharmaceutical channels.

Patients or clinicians seeking cosyntropin must either:

Explore diagnostic alternatives approved in their country
Investigate specific compassionate use or named patient programmes (rare and restrictive)
Consult with their national medicines regulator about special access pathways

The regulatory divergence between the US (where cosyntropin is FDA-approved) and the EU highlights how pharmaceutical approval is jurisdiction-specific. A compound's legality depends entirely on where you are.